This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Topalian, S. L. Articles by Wang, R.-F. Search for Related Content PubMed PubMed Citation Articles by Topalian, S. L. Articles by Wang, R.-F.

Revelation of a Cryptic Major Histocompatibility Complex Class II-restricted Tumor Epitope in a Novel RNA-processing Enzyme

Surgery Branch [S. L. T., M. I. G., X. W., R-F. W.] and Medicine Branch [Y. W.], National Cancer Institute, Center for Cancer Research, NIH, Bethesda, Maryland 20892-1502

CD4+ T-cell responses against human tumor antigens are a potentially critical component of the antitumor immune response. Molecular methods have been devised for rapidly identifying MHC class II-restricted tumor antigens and elucidating the recognized epitopes. We describe here the identification of neo-poly(A) polymerase (neo-PAP), a novel RNA processing enzyme overexpressed in a variety of human cancers, by screening a melanoma-derived invariant chain fusion cDNA library with tumor-reactive CD4+ T lymphocytes. A cryptic nonmutated HLA-DRß1*0701-restricted neo-PAP epitope was processed through the endogenous MHC class II pathway. A unique point mutation effected a nonconservative substitution of a leucine for a proline residue at a structurally important site in neo-PAP that was remote from the recognized peptide, revealing a normally silent epitope for immune recognition. Genetic aberrations such as the described point mutation can have unexpected immunological consequences, in this case leading to immune recognition of a distant normal self epitope.

This article has been cited by other articles:

				O. P. Cetinkol and N. V. Hud Molecular recognition of poly(A) by small ligands: an alternative method of analysis reveals nanomolar, cooperative and shape-selective binding Nucleic Acids Res., February 1, 2009; 37(2): 611 - 621. [Abstract] [Full Text] [PDF]

				M. Sensi and A. Anichini Unique Tumor Antigens: Evidence for Immune Control of Genome Integrity and Immunogenic Targets for T Cell-Mediated Patient-Specific Immunotherapy Clin. Cancer Res., September 1, 2006; 12(17): 5023 - 5032. [Abstract] [Full Text] [PDF]

				H. Y. Wang, G. Peng, Z. Guo, E. M. Shevach, and R.-F. Wang Recognition of a New ARTC1 Peptide Ligand Uniquely Expressed in Tumor Cells by Antigen-Specific CD4+ Regulatory T Cells J. Immunol., March 1, 2005; 174(5): 2661 - 2670. [Abstract] [Full Text] [PDF]

				K Kahnoski, S K Khoo, N T Nassif, J Chen, G P Lobo, E Segelov, and B T Teh Alterations of the Birt-Hogg-Dube gene (BHD) in sporadic colorectal tumours J. Med. Genet., July 1, 2003; 40(7): 511 - 515. [Full Text] [PDF]